
CAS
76985-52-9
Formulation
A crystalline solid
Purity
≥98%
MW
324,23894
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A guanidine-modified biotin derivative and an inhibitor of iNOS and nNOS (Kis = 21.8 and 37.5 µM for the mouse and rat enzymes, respectively); prevents hypoxia-ischemia-induced decreases in brain phosphocreatine and ATP levels and increases in edema in the parietal cortex and striatum, as well as reduces apoptosis in the parietal- and temporal cortex and striatum, in piglets at 0.2 mg/kg every four hours; increases survival of, and decreases electrographic seizures in, hypoxia-ischemia-injured piglets at 0.2 and 1 mg/kg every four hours; LNPs containing 2-iminobiotin conjugated to poly-L-lysine have been used to improve LNP tumor targeting, uptake, and retention compared with LNPs containing biotin conjugated to poly-L-lysine in rats
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).